ESR1 and breast carcinoma: More recently, investigation into the estrogenic specificity of SM6Met revealed that the extract displays three desirable estrogenic attributes for future development of a phytoestrogenic nutraceutical, namely, ERα antagonism, ERβ agonism, and also antagonism of E2-induced breast cancer cellular proliferation [32].